Akeso's (HKG:9926) ivonescimab drug showed strong positive results in a phase 3 trial in China for advanced squamous non-small cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.

The drug also met the primary endpoint of progression-free survival and a favorable safety profile in a trial with 532 enrollees, the filing said.

The trial assessed the capabilities of ivonescimab plus chemotherapy against tislelizumab plus chemotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer, the filing said.

Shares in the drug company nearly 5% during afternoon trading on Wednesday.